Form 8-K - Current report:
SEC Accession No. 0001564590-23-001611
Filing Date
2023-02-08
Accepted
2023-02-08 16:10:30
Documents
14
Period of Report
2023-02-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-8k_20230208.htm   iXBRL 8-K 34961
2 EX-99.1 vktx-ex991_6.htm EX-99.1 302453
3 GRAPHIC gnbh32dj1yhz000001.jpg GRAPHIC 13142
  Complete submission text file 0001564590-23-001611.txt   502867

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vktx-20230208.xsd EX-101.SCH 5629
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vktx-20230208_lab.xml EX-101.LAB 19329
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vktx-20230208_pre.xml EX-101.PRE 11516
8 EXTRACTED XBRL INSTANCE DOCUMENT vktx-8k_20230208_htm.xml XML 3561
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 23599194
SIC: 2834 Pharmaceutical Preparations